Nanotherapeutics and the Vaccine Branch of the National Cancer Institute Enter Into Cooperative Research and Development Agreement (CRADA)

Nanotherapeutics, Inc. announced today that it has entered into a two year Cooperative Research and Development Agreement (CRADA) with the Vaccine Branch of the National Cancer Institute (NCI) to produce HIV peptide oral vaccine nanoparticles using the company’s proprietary technology. The collaboration with NCI will employ the company’s nanoparticle delivery system, which enables oral targeted delivery of macromolecules such as peptides, to facilitate oral delivery in the GI tract to improve immune response.

James D. Talton, Ph.D., President of Nanotherapeutics and co-founder of the company, is the company’s principal investigator on the project. Dr. Talton said, “The CRADA marks a significant milestone for the company and an important step in the development of novel HIV vaccines. When the NCI came to us to request our help in their HIV oral vaccine project, naturally, we were excited that our technology was recognized by them and that the Vaccine Branch had chosen to collaborate with us in this vital area of HIV research and development.”

Also commenting on the CRADA, Mento A. “Chuck” Soponis, Chairman and CEO of Nanotherapeutics said, “This recognition is further validation of the work Dr. Talton and our scientists have been conducting over the past several years in the area of stabilized particle-based vaccine delivery. Entering into this collaborative relationship with the NCI’s Vaccine Branch, demonstrates both the scientific and competitive strength of Nanotherapeutics.”

In 2005, Nanotherapeutics received funding from National Institute on Drug Abuse (NIDA) to develop an oral nanoparticle medication to treat opiate addiction. The company also received funding from the National Institute of Allergy and Infectious Diseases (NIAID), as part of the National Institutes of Health (NIH) research program on Medical Countermeasures against Radiological and Nuclear Threats, to improve the delivery of an injectable treatment, and from Project Bioshield.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.